O22 Genetic lesions in multiple myeloma: prognostic and predictive significance in the era of the new drugs

✍ Scribed by R. Hajek; P. Kuglik; R. Zaoralova; H. Greslikova; P. Nemec; J. Smejkalova

• Book ID: 104323054
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 47 KB
• Volume: 21
• Category: Article
• ISSN: 0268-960X
• DOI: 10.1016/s0268-960x(07)70040-1

✦ Synopsis

note, in 19 patients, remission achieved by bortezomib-based therapy was consolidated by high-dose therapy followed by autologous stem cell transplantation. With a median follow-up time of 11 months (1 27 months), the median progression-free survival of our entire patient population is 13.8 month, while the median overall survival has not been reached yet. We conclude that in a real-life setting, such as the entire myeloma practice of our Department, impressive medium-term survival results may be achieved using bortezomib-based therapy.